LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

34.69 -5.58

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.52

Max

36.72

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5M -128M
Pardavimai	6.8M 11M
Pelnas, tenkantis vienai akcijai	-1.23
Pelno marža	-1,191.029
Darbuotojai	594
EBITDA	-18M -139M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+133.89% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-496M 3.9B
Ankstesnė atidarymo kaina	40.27
Ankstesnė uždarymo kaina	34.69

Naujienos nuotaikos

By Acuity

50%

136 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-17 23:53; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-17 23:50; UTC

Rinkos pokalbiai

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-17 23:36; UTC

Rinkos pokalbiai

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

2026-05-17 23:07; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Transactions Part of Group's Capital Reallocation Strategy

2026-05-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Share Sale Agreements Entered With Singland Properties

2026-05-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Divestments' Aggregate Consideration of S$299M in Cash

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Fund Stake Acquisition via Internal Resources

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire Stake for $389 Million

2026-05-17 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

2026-05-16 16:27; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

2026-05-16 15:26; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

2026-05-16 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

133.89% į viršų

12 mėnesių prognozė

Vidutinis 86 USD 133.89%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

136 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.